Department of Pharmaceutics, School of Pharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.
Department of Pharmaceutical Engineering, School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, 176 Xianghuai Road, Benxi, 117004, China.
AAPS PharmSciTech. 2018 Feb;19(2):700-709. doi: 10.1208/s12249-017-0872-4. Epub 2017 Oct 2.
The objective of this study was to develop an ocular drug delivery system built on the cationic liposomes, a novel bioadhesive colloidal system, which could enhance the precorneal residence time, ocular permeation, and bioavailability of ibuprofen. The optimal formulation of cationic liposomes prepared by ethanol injection method was ultimately confirmed by an orthogonal L (3) test design. In addition, γ-scintigraphic technology and the microdialysis technique were utilized in the assessment of in vivo precorneal retention capability and ocular bioavailability individually. In the end, we acquired the optimal formulation of ibuprofen cationic liposomes (Ibu-CL) by orthogonal test design, and the particle size and entrapment efficiency (EE%) were 121.0 ± 3.5 nm and 72.9 ± 3.4%, respectively. In comparison to ibuprofen eye drops (Ibu-ED), Ibu-CL could significantly prolong the T to 100 min and the AUC to 1.53-folds, which indicated that the Ibu-CL could improve the precorneal retention time and bioavailability of ibuprofen. Consequently, these outcomes designated that the ibuprofen cationic liposomes we researched probably are a promising application in ocular drug delivery system.
本研究旨在开发一种基于阳离子脂质体的眼部给药系统,这是一种新型的生物黏附胶体系统,可增强布洛芬的角膜前停留时间、眼部渗透和生物利用度。最终通过正交 L (3) 试验设计确定了乙醇注入法制备阳离子脂质体的最佳配方。此外,γ闪烁照相技术和微透析技术分别用于评估体内角膜前滞留能力和眼部生物利用度。最终,我们通过正交试验设计获得了最佳的布洛芬阳离子脂质体(Ibu-CL)配方,其粒径和包封率(EE%)分别为 121.0 ± 3.5nm 和 72.9 ± 3.4%。与布洛芬滴眼液(Ibu-ED)相比,Ibu-CL 可显著延长 T 至 100min 和 AUC 至 1.53 倍,表明 Ibu-CL 可提高布洛芬的角膜前滞留时间和生物利用度。因此,这些结果表明,我们研究的布洛芬阳离子脂质体可能是眼部药物传递系统的一种有前途的应用。